Bone Marrow Concentrate for Hip Osteoarthritis (Registry Results)

Objective

Describe safety and functional outcomes following intra-articular bone marrow concentrate (BMC) for hip osteoarthritis.

Methods

Prospective registry analysis of patients treated with BMC. Outcomes included pain reporting, Oxford Hip Score (OHS), and subjective percent improvement; adjunct PRP/PL was used per protocol in some cases.

Key Results

• Improvements reported in pain and function (OHS) over follow-up.
• Safety: Registry reported no serious complications.
• Subgroup trends suggested younger age groups may experience larger improvements.

Conclusion

Registry outcomes suggested symptomatic improvement with an acceptable safety profile after BMC for hip OA; registry designs carry inherent limitations.